CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027



November 28, 2022




U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Attention: Doris Stacey Gama



CNS Pharmaceuticals, Inc.

Registration Statement on Form S-1

Registration No. 333-267975



Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 1:00 P.M. (Eastern Time) on November 29, 2022, or as soon thereafter as possible on such date.



Very truly yours,


CNS Pharmaceuticals, Inc.

  By: /s/Christopher Downs

  Name: Christopher Downs

  Title: Chief Financial Officer